Connect to share and comment

FDA advisers vote against approval for Depomed's menopause drug

PlacardEnlarge
(Globalpost/GlobalPost)

March 4 (Reuters) - Advisers to the U.S. Food and Drug Administration on Monday recommended the agency reject a drug made by Depomed Inc to reduce the frequency and severity of hot flashes associated with menopause.

The panel of advisers voted 12-2 against the drug, Sefelsa, which is a long-acting version of the epilepsy drug gabapentin. The panel concluded that the drug's modest efficacy did not outweigh the side effects. (Reporting By Toni Clarke; Editing by Gerald E. McCormick)

http://www.globalpost.com/dispatch/news/thomson-reuters/130304/fda-advisers-vote-against-approval-depomeds-menopause-drug